692 related articles for article (PubMed ID: 19463512)
21. Long-term clinical outcomes of sirolimus- versus paclitaxel-eluting stents for patients with unprotected left main coronary artery disease: analysis of the MAIN-COMPARE (revascularization for unprotected left main coronary artery stenosis: comparison of percutaneous coronary angioplasty versus surgical revascularization) registry.
Lee JY; Park DW; Yun SC; Lee SW; Kim YH; Lee CW; Hong MK; Park SW; Park SJ
J Am Coll Cardiol; 2009 Aug; 54(9):853-9. PubMed ID: 19695467
[TBL] [Abstract][Full Text] [Related]
22. Outcome differences with the use of drug-eluting stents for the treatment of in-stent restenosis of bare-metal stents versus drug-eluting stents.
Steinberg DH; Gaglia MA; Pinto Slottow TL; Roy P; Bonello L; De Labriolle A; Lemesle G; Torguson R; Kineshige K; Xue Z; Suddath WO; Kent KM; Satler LF; Pichard AD; Lindsay J; Waksman R
Am J Cardiol; 2009 Feb; 103(4):491-5. PubMed ID: 19195508
[TBL] [Abstract][Full Text] [Related]
23. Offsetting impact of thrombosis and restenosis on the occurrence of death and myocardial infarction after paclitaxel-eluting and bare metal stent implantation.
Stone GW; Ellis SG; Colombo A; Dawkins KD; Grube E; Cutlip DE; Friedman M; Baim DS; Koglin J
Circulation; 2007 Jun; 115(22):2842-7. PubMed ID: 17515458
[TBL] [Abstract][Full Text] [Related]
24. Comparison of drug-eluting stents and bare-metal stents for the treatment of unprotected left main coronary artery disease in acute coronary syndromes.
Tamburino C; Di Salvo ME; Capodanno D; Palmerini T; Sheiban I; Margheri M; Vecchi G; Sangiorgi G; Piovaccari G; Bartorelli A; Briguori C; Ardissino D; Di Pede F; Ramondo A; Inglese L; Petronio AS; Bolognese L; Benassi A; Palmieri C; Filippone V; De Servi S
Am J Cardiol; 2009 Jan; 103(2):187-93. PubMed ID: 19121434
[TBL] [Abstract][Full Text] [Related]
25. A multicenter, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: cortisone plus BMS or DES versus BMS alone to eliminate restenosis (CEREA-DES) - study design and rationale.
Ribichini F; Tomai F; De Luca G; Boccuzzi G; Presbitero P; Pesarini G; Ferrero V; Ghini AS; Pastori F; De Luca L; Zavalloni D; Soregaroli D; Garbo R; Franchi E; Marino P; Minelli M; Vassanelli C
J Cardiovasc Med (Hagerstown); 2009 Feb; 10(2):192-9. PubMed ID: 19377384
[TBL] [Abstract][Full Text] [Related]
26. Two-year clinical outcomes with drug-eluting stents for diabetic patients with de novo coronary lesions: results from a real-world multicenter registry.
Ortolani P; Balducelli M; Marzaroli P; Piovaccari G; Menozzi A; Guiducci V; Sangiorgio P; Tarantino F; Geraci G; Castriota F; Tondi S; Saia F; Cooke RM; Guastaroba P; Grilli R; Marzocchi A; Maresta A
Circulation; 2008 Feb; 117(7):923-30. PubMed ID: 18250265
[TBL] [Abstract][Full Text] [Related]
27. Impact of drug-eluting stents on outcomes of patients with end-stage renal disease undergoing percutaneous coronary revascularization.
Das P; Moliterno DJ; Charnigo R; Mukherjee D; Steinhubl SR; Sneed JD; Booth DC; Ziada KM
J Invasive Cardiol; 2006 Sep; 18(9):405-8. PubMed ID: 16954577
[TBL] [Abstract][Full Text] [Related]
28. Long-term safety and effectiveness of drug-eluting stents compared to bare metal stents following successful PCI in non-ST-elevation myocardial infarction: findings from the Guthrie Health Off-Label StenT (GHOST) Registry.
Harjai KJ; Sattur S; Orshaw P; Boura J
J Interv Cardiol; 2012 Feb; 25(1):28-36. PubMed ID: 21981467
[TBL] [Abstract][Full Text] [Related]
29. Target lesion revascularization after bare-metal or drug-eluting stents: clinical presentations and outcomes.
Hayes KR; Applegate RJ; Sacrinty MT; Kutcher MA; Gandhi SK; Santos RM; Little WC
J Invasive Cardiol; 2010 Jun; 22(6):266-70. PubMed ID: 20516505
[TBL] [Abstract][Full Text] [Related]
30. Long-term benefit-risk balance of drug-eluting vs. bare-metal stents in daily practice: does stent diameter matter? Three-year follow-up of BASKET.
Pfisterer M; Brunner-La Rocca HP; Rickenbacher P; Hunziker P; Mueller C; Nietlispach F; Leibundgut G; Bader F; Kaiser C;
Eur Heart J; 2009 Jan; 30(1):16-24. PubMed ID: 19033260
[TBL] [Abstract][Full Text] [Related]
31. Clinical outcomes following percutaneous coronary intervention with drug-eluting vs. bare-metal stents in dialysis patients.
Halkin A; Selzer F; Marroquin O; Laskey W; Detre K; Cohen H
J Invasive Cardiol; 2006 Dec; 18(12):577-83. PubMed ID: 17197706
[TBL] [Abstract][Full Text] [Related]
32. A single center investigation of bare-metal or drug-eluting stent restenosis from 1633 consecutive Chinese Han ethnic patients.
Xu B; Li JJ; Yang YJ; Ma WH; Chen JL; Qiao SB; Qin XW; Yao M; Liu HB; Wu YJ; Yuan JQ; Chen J; You SJ; Dai J; Xia R; Gao RL
Chin Med J (Engl); 2006 Apr; 119(7):533-8. PubMed ID: 16620692
[TBL] [Abstract][Full Text] [Related]
33. Comparison of coronary artery stenting outcomes in the eras before and after the introduction of drug-eluting stents.
Hannan EL; Racz M; Holmes DR; Walford G; Sharma S; Katz S; Jones RH; King SB
Circulation; 2008 Apr; 117(16):2071-8. PubMed ID: 18391112
[TBL] [Abstract][Full Text] [Related]
34. Effect of coronary target lesion revascularization on late cardiac events after insertion of sirolimus-eluting or bare metal stents.
Novack V; Nguyen MC; Rooney M; Chacko R; Novack L; Pencina M; Apruzzese P; Mauri L; Cohen SA; Moses J; Leon MB; Cutlip DE
Am J Cardiol; 2010 Sep; 106(6):774-9. PubMed ID: 20816116
[TBL] [Abstract][Full Text] [Related]
35. Comparison of six-month outcomes for primary percutaneous revascularization for acute myocardial infarction with drug-eluting versus bare metal stents (from the APEX-AMI study).
Patel MR; Pfisterer ME; Betriu A; Widmisky P; Holmes DR; O'Neill WW; Stebbins A; Van de Werf F; Armstrong PW; Granger CB;
Am J Cardiol; 2009 Jan; 103(2):181-6. PubMed ID: 19121433
[TBL] [Abstract][Full Text] [Related]
36. Safety and effectiveness of drug-eluting and bare-metal stents for patients with off- and on-label indications.
Ko DT; Chiu M; Guo H; Austin PC; Goeree R; Cohen E; Labinaz M; Tu JV
J Am Coll Cardiol; 2009 May; 53(19):1773-82. PubMed ID: 19422984
[TBL] [Abstract][Full Text] [Related]
37. Lack of clinical long-term benefit with the use of a drug eluting stent compared to use of a bare metal stent in saphenous vein grafts.
Gioia G; Benassi A; Mohendra R; Chowdhury K; Masood I; Matthai W
Catheter Cardiovasc Interv; 2008 Jul; 72(1):13-20. PubMed ID: 18561143
[TBL] [Abstract][Full Text] [Related]
38. Clinical outcomes after multilesion percutaneous coronary intervention: comparison between exclusive and selective use of drug-eluting stents.
Bertrand OF; Faurie B; Larose E; Nguyen CM; Gleeton O; Déry JP; Noël B; Proulx G; Roy L; Costerousse O; De Larochellière R; Rodés-Cabau J
J Invasive Cardiol; 2008 Mar; 20(3):99-104. PubMed ID: 18316823
[TBL] [Abstract][Full Text] [Related]
39. Clinical outcomes after heterogeneous overlap stenting with drug-eluting stents and bare-metal stents for de novo coronary artery narrowings.
Aoki J; Kirtane AJ; Dangas GD; Lansky AJ; Morales A; Kimura M; Kim YH; Moussa I; Weisz G; Kreps EM; Collins M; Frankin-Bond T; Stone GW; Moses JW; Leon MB; Mehran R
Am J Cardiol; 2008 Jan; 101(1):58-62. PubMed ID: 18157966
[TBL] [Abstract][Full Text] [Related]
40. Drug-eluting or bare-metal stenting in patients with diabetes mellitus: results from the Massachusetts Data Analysis Center Registry.
Garg P; Normand SL; Silbaugh TS; Wolf RE; Zelevinsky K; Lovett A; Varma MR; Zhou Z; Mauri L
Circulation; 2008 Nov; 118(22):2277-85, 7p following 2285. PubMed ID: 19001019
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
